ES
53
-2
PBI
32
-3
DTE
45
-2
NTRS
49
-3
MRO
59
-3
CMA
52
-3
NKE
30
2
CHRW
37
-13
ORLY
54
-3
SPG
48
-5
HCA
48
-2
ABT
62
9
CA
10
-3
ADP
61
-3
DOV
57
-2
USB
46
-2
HON
58
3
SYY
52
11
AMZN
56
5
KMI
65
-4
ES
53
-2
PBI
32
-3
DTE
45
-2
NTRS
49
-3
MRO
59
-3
CMA
52
-3
NKE
30
2
CHRW
37
-13
ORLY
54
-3
SPG
48
-5
HCA
48
-2
ABT
62
9
CA
10
-3
ADP
61
-3
DOV
57
-2
USB
46
-2
HON
58
3
SYY
52
11
AMZN
56
5
KMI
65
-4
Financhill
Back

Aquestive Therapeutics 10K Form

Buy
63

AQST
Aquestive Therapeutics

Last Price:
5.15
Seasonality Move:
-3.4%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AQST News And Ratings

See the #1 stock for the next 7 days that we like better than AQST

AQST Financial Statistics

Sales & Book Value

Annual Sales: $50.58M
Cash Flow: $-7.04M
Price / Cash Flow: 0
Annual Sales: $-0.39
Price / Book: 0

Profitability

EPS (TTM): -0.36410
Net Income (TTM): $-25.72M
Gross Margin: $29.75M
Return on Equity: 0%
Return on Assets: -30.55%

Aquestive Therapeutics Earnings Forecast

Key Aquestive Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 8 years for AQST is 58.82%.
  • The Selling, General & Administrative Expenses for AQST have been equal to 62.77% of Gross Profit Margin.
  • The Research & Development expenses have been 25.91% of Revenue.
  • The Interest Expense is -94.82% of Operating Income.
  • The Net Earning history of AQST is -15.56% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 4 years.

Aquestive Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AQST
CUSIP: 03843E
Website: aquestive.com

Debt

Debt-to-Equity Ratio: -0.85
Current Ratio: 7.49
Quick Ratio: 6.9

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AQST Technical Analysis vs Fundamental Analysis

Buy
63
Aquestive Therapeutics (AQST) is a Buy

Is Aquestive Therapeutics a Buy or a Sell?